Mechanism-based inhibition of rat liver microsomal diazepam C3-hydroxylase by mifepristone associated with loss of spectrally detectable cytochrome P450

Chemico-Biological Interactions

Volumn 118, Issue 1, 1999, Pages 39-49

  Reilly, Paul E B ^a   Gomi, Rebecca J ^a   Mason, Steven R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

CYP3A; Cytochrome P450; Dexamethasone; Diazepam C3 hydroxylase; Food deprivation; Heme thiolate protein; Mechanism based inhibition; Mifepristone; Monooxygenase induction; RU486

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DIAZEPAM; MIFEPRISTONE; OXYGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME BINDING; ENZYME INHIBITION; ENZYME MODIFICATION; ENZYME STRUCTURE; FEMALE; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER METABOLISM; LIVER MICROSOME; NONHUMAN; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; KINETICS; MICROSOMES, LIVER; MIFEPRISTONE; MIXED FUNCTION OXYGENASES; NADP; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, WISTAR; SUBSTRATE SPECIFICITY;

EID: 0033022801     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(98)00115-X     Document Type: Article

References (32)

1. D. Philibert, R. Dereadt, G. Teutsch, C. Tournemine, E. Sakiz, RU38486 a new lead for steroid antihormones, Abstract 668, 64th Annu. Meet. Endocrinol. Soc., San Francisco, (1982).
2. Heikinheimo O. Antiprogesterone steroid RU486: pharmacokinetics and receptor binding in humans. Acta Obstet. Gynecol. Scand. 69:1990;357-358.
3. Heikinheimo O., Ylikorkala O., Lahteenmaki P. Antiprogesterone RU486-a drug for non-surgical abortion. Ann. Med. 22:1990;75-84.
4. Van der Lely A., Foeken K., van der Mast R., Lamberts S.W. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann. Intern. Med. 114:1991;143-144.
5. Bakker G.H., Seyteno-Han B., Portengen H., De Jong F.H., Foekens J.A., Klijn J.G. Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies. J. Steroid Biochem. Molec. Biol. 37:1990;789-794.
6. Schneider M.R., Michna H., Nishino Y., el Etreby M.F. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J. Steroid Biochem. Molec. Biol. 37:1990;783-787.
7. Michna H., Nishino Y., Neef G., McGuire W.L., Schneider M.R. Progesterone antagonists: tumor-inhibiting potential and mechanism of action. J. Steroid Biochem. Molec. Biol. 41:1992;339-348.
8. Lin M.F., Kawachi M.H., Stallcup M.R., Grunberg S.M., Lin F.F. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate. 26:1995;194-204.
9. Schmidt M., Löffler G. Mifepristone is a potent inhibitor of aromatase induction in human breast adipose tissue stromal cells. J. Steroid Biochem. Molec. Biol. 60:1997;197-204.
10. Jang G.R., Wrighton S.A., Benet L.Z. Identification of CYP3A4 as the principal enzyme catalysing mifepristone (RU 486) oxidation in human liver microsomes. Biochem. Pharmacol. 52:1996;753-761.
11. Chasserot-Golaz S., Ribeiro V., Genot G., Lechner M.C., Beck G. The steroid antagonist RU38486 is metabolised by the liver microsomal P450 mono-oxygenases. Biochem. Biophys. Res. Comm. 167:1990;1271-1278.
12. Chasserot-Golaz S., Beck G., Venetianer A. Biotransformation of 17(-hydroxy-11((4-dimethylaminophenyl)-17(-1-propyl-estra-4,9-dien-3-one (RU486) in rat hepatoma variants. Biochem. Pharmacol. 46:1993;2100-2103.
13. White I.N.H., Muller-Eberhard U. Decreased liver cytochrome P450 in rats caused by norethindrone or ethynyloestradiol. Biochem. J. 166:1977;57-64.
14. Ortiz de Montellano P.R., Kunze K.L., Yost G.S., Mico B.A. Self-catalyzed destruction of cytochrome P450: covalent binding of ethynyl sterols to prosthetic heme. Proc. Natl. Acad. Sci. USA. 76:1979;746-749.
15. Ortiz de Montellano P.R., Komives E.A. Branchpoint for heme alkylation and metabolise formation in the oxidation of aryl acetylenes. J. Biol. Chem. 260:1985;3330-3336.
16. Guengerich F.P. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by Gestodene. Chem. Res. Tox. 3:1990;363-371.
17. O'N. Johnston J., Wright C.L., Leeson G.A. Regioselectivity of metabolic activation of acetylenic steroids by hepatic cytochrome P-450 isozymes. Steroids. 56:1990;180-184.
18. Olakanmi O., Seybert D.W. Modified acetylenic steroids as potent mechanism-based inhibitors of cytochrome P-450scc. J. Steroid Biochem. 36:1990;273-280.
19. Chan W.K., Sui Z., Ortiz de Montellano P.R. Determinants of protein modification versus heme alkylation: Inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene. Chem. Res. Toxicol. 6:1993;38-45.
20. P.R. Ortiz de Montellano, M.A. Correia, Inhibition of cytochrome P450 enzymes, in: Paul Ortiz de Montellano (Ed.), Cytochrome P450 Structure, Mechanism and Biochemistry, Plenum Press, New York, 1995, Chapter 9.
21. Helvig C., Alayrac C., Mioskowski C., Koop D., Poullain D., Durst F., Salaün J-P. Suicide inactivation of cytochrome P450 by mid-chain and terminal acetylenes. J. Biol. Chem. 272:1997;414-421.
22. Foroozesh M., Primrose G., Guo Z., Bell L.C., Alworth W. L., Guengerich F.P. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem. Res. Toxicol. 10:1997;91-102.
23. Cheesman M.J., Mason S.R., Reilly P.E.B. Effects of food deprivation and adrenalectomy on CYP3A induction by RU486 in female rats. J. Steroid Biochem. Mol. Biol. 58:1996;447-454.
24. Guengerich F.P. Analysis and characterisation of enzymes. Hayes A.W. Principles and Methods of Toxicology. 1994;1259-1313 Raven Press Ltd, New York.
25. 3-hydroxylation of diazepam and nordazepam but not N-dealkylation of diazepam and temazepam. Mol. Pharmacol. 37:1990;767-774.
26. Strotkamp D., Roos P.H., Hanstein W.G. A novel CYP3 gene from female rats. Biochim. Biophys. Acta. 1260:1995;341-344.
27. Reilly P.E.B., Mason S.R., Hooper W.D. Effects of ethinylestradiol and testosterone implants on hepatic microsomal cytochrome P450 monooxygenases of birth gonadectomized male and female dark agouti rats. J. Steroid Biochem. Mol. Biol. 39:1991;741-749.
28. Mahnke A., Strotkamp D., Roos P.H., Hanstein W.G., Chabot G.G., Nef P. Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Arch. Biochem. Biophys. 337:1997;62-68.
29. Neville C.F., Ninomiya S.-I., Shimada N., Kamataki T., Imaoka S., Funae Y. Characterisation of specific cytochrome P450 enzymes responsible for the metabolism of diazepam in hepatic microsomes of adult male rats. Biochem. Pharmacol. 45:1993;59-65.
30. Jang G.R., Benet L.Z. Antiprogestin-mediated inactivation of cytochrome P450 3A4. Pharmacology. 56:1998;150-157.
31. Franklin M.R. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Meth. Enzymol. 206:1991;559-573.
32. Thummel K.E., Wilkinson G.R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. 38:1998;389-430.